These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19019258)

  • 1. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Stearns V; Rae JM
    Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of anti-estrogen treatment of breast cancer.
    Del Re M; Michelucci A; Simi P; Danesi R
    Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
    Goetz MP; Kamal A; Ames MM
    Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
    Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
    J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
    Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
    Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of tamoxifen therapy.
    Brauch H; Mürdter TE; Eichelbaum M; Schwab M
    Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen and CYP2D6: a contradiction of data.
    Hertz DL; McLeod HL; Irvin WJ
    Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized tamoxifen: a step closer but miles to go.
    Bardia A; Stearns V
    Clin Cancer Res; 2010 Sep; 16(17):4308-10. PubMed ID: 20651057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.
    Higgins MJ; Stearns V
    Curr Oncol Rep; 2010 Jan; 12(1):7-15. PubMed ID: 20425602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
    Lammers LA; Mathijssen RH; van Gelder T; Bijl MJ; de Graan AJ; Seynaeve C; van Fessem MA; Berns EM; Vulto AG; van Schaik RH
    Br J Cancer; 2010 Sep; 103(6):765-71. PubMed ID: 20700120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
    Briest S; Stearns V
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.